Headlands Research

Headlands Research Contact information, map and directions, contact form, opening hours, services, ratings, photos, videos and announcements from Headlands Research, Healthcare administrator, Lake Worth, FL.

We're highlighting Dr. Kinan Hreib, Medical Director and Principal Investigator at Headlands Research Eastern Massachuse...
12/19/2025

We're highlighting Dr. Kinan Hreib, Medical Director and Principal Investigator at Headlands Research Eastern Massachusetts (EMA).

Dr. Hreib holds an MD, MBA, and PhD from Boston University and completed his medical and neurology training at Boston University Medical Center and Boston City Hospital. His career spans decades of clinical leadership and neurological expertise, beginning with more than 20 years as Director of Vascular Neurology at Lahey Clinic.

He later served as Chief of Neurology at Mount Auburn Hospital and then as Chief Medical Officer for Baystate Health North, where he continued practicing neurology while overseeing clinical operations.

Driven by a deep commitment to patients affected by neurodegenerative diseases, Dr. Hreib brings both compassion and scientific rigor to his work at Headlands Research EMA. His leadership is central to advancing research that supports better understanding and improved treatments for neurological conditions.

We are honored to have Dr. Hreib’s experience, vision, and dedication within the Headlands Research network.

We are pleased to highlight Dr. Timothy Bailey, President of Headlands Research – AMCR Institute in Escondido, Californi...
12/15/2025

We are pleased to highlight Dr. Timothy Bailey, President of Headlands Research – AMCR Institute in Escondido, California.

As an interventional endocrinologist, Dr. Bailey has served as Principal Investigator on more than 200 Phase I–IV clinical trials focused on diabetes therapies, including investigational medications, sensors, delivery devices, and automated insulin delivery (“artificial pancreas”) systems. His research has contributed to greater innovation and access in diabetes management.

Dr. Bailey has authored over 150 peer-reviewed publications and has a particular focus on medical devices, human factors research, and real-world evidence, all aimed at improving therapy adherence, persistence, and outcomes for people living with diabetes.

With nearly 40% of people with diabetes affected by kidney disease, emerging science is reshaping how we understand and ...
12/12/2025

With nearly 40% of people with diabetes affected by kidney disease, emerging science is reshaping how we understand and treat diabetic nephropathy. In this new blog post, David Halpert, MD, Principal Investigator at JEM Research Institute, breaks down the complex pathways driving kidney damage and highlights how new therapies are moving beyond glucose and blood pressure control to target inflammation, fibrosis, and oxidative stress directly.

From the expanding roles of SGLT2 inhibitors, MRAs, and GLP-1 RAs to promising dual-agonists and novel cellular targets, the future of care is shifting toward treatments that can truly preserve kidney function and potentially alter disease progression.

Read Dr. Halpert's blog post to explore where research is headed and what it means for patients: https://headlandsresearch.com/blogs/the-next-frontier-in-diabetic-nephropathy-protection-preservation-and-true-progress/

Earlier this year, Lawrence Sher, MD, FAAP, FAAAA, FACAAI, Associate Medical Director of Peninsula Research Associates, ...
12/10/2025

Earlier this year, Lawrence Sher, MD, FAAP, FAAAA, FACAAI, Associate Medical Director of Peninsula Research Associates, a Headlands Research site, co-authored a phase 3 study evaluating the mRNA-1010 quadrivalent influenza vaccine.

Published in Vaccine, this large-scale trial demonstrated that a single 50-μg dose of mRNA-1010 elicited stronger immune responses than licensed standard-dose and high-dose influenza vaccines, with a favorable safety profile and no major safety concerns.

These findings highlight the potential of mRNA-based technology to transform seasonal influenza prevention.

Read more: https://headlandsresearch.com/news/a-phase-3-randomized-safety-and-immunogenicity-trial-of-mrna-1010-seasonal-influenza-vaccine-in-adults/

A big congratulations to Heather Manley, Site Director at Clinvest, for co-authoring a new study that explores how non-t...
12/09/2025

A big congratulations to Heather Manley, Site Director at Clinvest, for co-authoring a new study that explores how non-traditional, community-embedded research sites, known as frontier sites, can help address the industry’s growing capacity challenges.

The research, conducted through the Site Enablement League (SEL) Task Force, shows that frontier sites offer meaningful opportunities to reach underserved populations and expand trial access. Survey findings point to clear benefits in participant diversity and community engagement, alongside operational and compliance challenges that require targeted support.

This work, published in Contemporary Clinical Trials Communications, lays the foundation for developing a future industry playbook to successfully integrate frontier sites into clinical trial operations.

Read more: https://headlandsresearch.com/news/frontier-sites-in-clinical-trials-opportunities-challenges-and-models/

We’re pleased to highlight Dr. David Halpert, Principal Investigator at JEM Research Institute, part of the Headlands Re...
12/08/2025

We’re pleased to highlight Dr. David Halpert, Principal Investigator at JEM Research Institute, part of the Headlands Research site network.

Dr. Halpert is a board-certified physician specializing in internal medicine and nephrology, with more than 30 years of clinical experience. He earned his medical degree from Rush Medical College and has held multiple leadership roles throughout his career.

As a clinical researcher, Dr. Halpert has served as principal investigator or sub-investigator on over 50 clinical trials spanning therapeutic areas such as cardiometabolic, central nervous system conditions, and vaccines, helping to bring new therapeutic options forward for patients.

We are proud to have Dr. Halpert’s expertise and commitment to advancing patient care within the Headlands Research network.

Great to bring together colleagues from across the Headlands Research network at CTAD this week in San Diego!From our co...
12/05/2025

Great to bring together colleagues from across the Headlands Research network at CTAD this week in San Diego!

From our corporate team to leaders across our sites, we’re energized by the innovation, collaboration, and shared commitment to advancing Alzheimer’s research.

Our entire team is grateful for the opportunity to connect, learn, and keep pushing for better solutions for patients and families.

Pictured here:
• Donald Marks, Principal Investigator at Headlands Research – EMA
• Jason Agran, Principal Investigator at Clinical Research Atlanta (CRA)
• Mark Goldstein, Senior Advisor, Neuroscience at JEM Research Institute
• Lawrence Sher, Associate Medical Director and Principal Investigator (PI) at Peninsula Research Associates, and Medical Director at Headlands Research
• Nella Green, Principal Investigator at Artemis Institute for Clinical Research
• Scott Losk, Principal Investigator at Summit Research
• Uzma Khan, Principal Investigator at Headlands Research Orlando
• Ian Cohen, President and Research Investigator at Toronto Memory Program
• Belinda Russell, Director of CNS Excellence
• Linda Pao, Medical Director and Principal Investigator at JEM Research Institute
• Guinevere McCormick, Director of Operations at Artemis Institute for Clinical Research
• Stacey Layle, Principal Investigator at Artemis Institute for Clinical Research
• Jordan Wertheimer, Director of Business Development
• Mauro Ormedilla, Senior Regional Director of Operations (West Coast)
• Matthew Ajello, Site Director at Artemis Institute for Clinical Research

We’re excited to spotlight Dr. Jason Agran, Principal Investigator at Clinical Research Atlanta (CRA), part of the Headl...
12/05/2025

We’re excited to spotlight Dr. Jason Agran, Principal Investigator at Clinical Research Atlanta (CRA), part of the Headlands Research site network.

Dr. Agran is a board-certified Emergency Medicine Physician with both an MD and a PhD in Neuroscience, and post-doctoral training in advanced neuroimaging. His career bridges frontline clinical care, scientific research, and medical innovation.

As a Principal Investigator, Dr. Agran is dedicated to translating real-world patient experiences into research that advances the future of medicine. His work reflects a steadfast commitment to ethical, safety-first, data-driven discovery and a deep belief in the power of medical science to improve lives.

We are proud to have Dr. Agran’s leadership and expertise within the Headlands Research network.

12/03/2025

For Dr. Lawrence Sher, Associate Medical Director and PI at PRA, education and teamwork are at the heart of clinical research success.

“When everyone understands the science, they can teach and empower patients, and that’s when research becomes fun,” he says. “I want to laugh, I want to teach, and when challenges happen, our motto is simple: hakuna matata. We move forward together.”

At PRA, Dr. Sher and his team lead with knowledge, positivity, and collaboration, making every study a shared success.

Read more about Dr. Sher’s approach to research and leadership: https://headlandsresearch.com/blogs/spotlight-on-dr-lawrence-sher-advancing-allergy-immunology-and-patient-care-through-research/

We’re pleased to share that Christopher Romero, MD, PhD, FACP, Medical Director at Headlands Research and Principal Inve...
12/01/2025

We’re pleased to share that Christopher Romero, MD, PhD, FACP, Medical Director at Headlands Research and Principal Investigator at Headlands Research Brownsville, collaborated on a phase 2 study evaluating maridebart cafraglutide (MariTide), a novel long-acting peptide-antibody conjugate designed to treat obesity.

The study, published in the New England Journal of Medicine, found that once-monthly administration of MariTide led to substantial and sustained weight reduction in participants with obesity, with or without type 2 diabetes, and favorable effects on glycemic control.

Read the full publication: https://headlandsresearch.com/news/once-monthly-maridebart-cafraglutide-for-the-treatment-of-obesity/

This Thanksgiving, we’re grateful for the incredible participants, dedicated staff, and research partners who make our w...
11/27/2025

This Thanksgiving, we’re grateful for the incredible participants, dedicated staff, and research partners who make our work possible. Your trust and commitment drive our mission to advance medicine and improve health for communities everywhere.

From all of us at Headlands Research, we wish you and your loved ones a safe and joyful holiday!

Are you attending the 2025 Scottsdale Headache Symposium from the American Headache Society? Schedule a time to chat wit...
11/25/2025

Are you attending the 2025 Scottsdale Headache Symposium from the American Headache Society? Schedule a time to chat with one of our experts at the event to learn how our network of clinical trial sites can support the recruitment of diverse and specialty patient populations while delivering the highest quality data for your headache and migraine research.

Meet our attendees:

• Lauren Chazal, Chief Business Development Officer at Headlands Research
• Ryan Cady, Director of Cardiometabolic and Pain Strategy at Headlands Research

https://headlandsresearch.com/events/2025-scottsdale-headache-symposium/

Address

Lake Worth, FL

Website

Alerts

Be the first to know and let us send you an email when Headlands Research posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category